Table 2.

Treatment details.

	NUMBER (%) (TOTAL = 249)
Induction chemotherapy
None	95 (38.2%)
Docetaxel/cisplatin/5-fluorouracil	55 (22.1%)
Cisplatin or carboplatin with 5-fluorouracil	96 (38.6%)
Other	3 (5.2%)
Concurrent chemotherapy
Cisplatin	216 (86.7%)
Carboplatin	21 (8.4%)
Planned but not given after induction chemotherapy	12 (4.8%)
No. Cycles concurrent chemotherapy
0	12 (4.8%)
1	70 (28.1%)
2	145 (58.2%)
3	22 (8.8%)
Radiation dose
70 Gy in 35 fractions	186 (74.7%)
68 Gy in 34 fractions	13 (52.2%)
66 Gy in 33 fractions	8 (3.2%)
65 Gy in 30 fractions	19 (7.6%)
56 Gy in 20 fractions	21 (8.4%)
Not received	2 (0.8%)
Neutrophil-to-lymphocyte ratio pre-treatment
≤5	196 (78.7%)
>5	50 (20.1%)
Missing data	3 (1.2%)
Platelet-to-lymphocyte ratio pre-treatment
≤150	109 (43.8%)
>150≤300	116 (46.6%)
>300	21 (8.4%)
Missing data	3 (1.2%)